Skip to main content

PDS Biotechnology Corp

PDSB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001472091

No open-market purchases or sales by PDS Biotechnology Corp insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $6.78M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding PDS Biotechnology Corp changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of PDSB: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders8078−2
Shares7.93M7.86M−70.5K (−0.9%)
Value$39.9M$39.7M−$199.4K (−0.5%)

New holders (10)

Institutions that held PDS Biotechnology Corp at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to PDSB in Q3 2023
InstitutionSharesValue% of portfolio
Trexquant Investment LP25,851$130.5K0.00%
Raymond James & Associates24,361$123.0K0.00%
AQR Capital Management LLC22,427$113.3K0.00%
Corton Capital Inc.22,091$111.6K0.06%
Rathbone Brothers plc15,000$75.8K0.00%
Raymond James Financial Services Advisors, Inc.11,154$56.3K0.00%
EP Wealth Advisors, LLC10,207$51.5K0.00%
Allspring Global Investments Holdings, LLC5,997$30.3K0.00%
JJJ Advisors Inc.287$1.45K0.00%
Russell Investments Group, Ltd.109$5500.00%

Sold out (12)

Institutions that held PDS Biotechnology Corp at the end of Q2 2023 and filed for Q3 2023 without it.